Stockscreener 앱 받기
19.05
2.21%
-0.43
시간 외 거래:
18.85
-0.20
-1.05%
전일 마감가:
$19.48
열려 있는:
$19.37
하루 거래량:
1.20M
Relative Volume:
0.64
시가총액:
$1.69B
수익:
$217.42M
순이익/손실:
$-243.25M
주가수익비율:
-6.8153
EPS:
-2.7952
순현금흐름:
$-278.35M
1주 성능:
-8.46%
1개월 성능:
-12.85%
6개월 성능:
-6.20%
1년 성능:
+92.04%
1일 변동 폭
$18.64
$19.50
1주일 범위
$18.64
$21.57
52주 변동 폭
$9.49
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
명칭
Syndax Pharmaceuticals Inc
전화
781-419-1400
주소
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
19.05 | 1.82B | 217.42M | -243.25M | -278.35M | -2.7952 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-16 | 재개 | H.C. Wainwright | Buy |
| 2025-09-10 | 재개 | Stifel | Buy |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-08-05 | 재확인 | BTIG Research | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-06-28 | 개시 | Jefferies | Buy |
| 2024-01-31 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-10-25 | 개시 | BofA Securities | Buy |
| 2023-10-11 | 개시 | Goldman | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-11 | 개시 | Guggenheim | Buy |
| 2023-04-17 | 재개 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2023-01-03 | 개시 | JP Morgan | Overweight |
| 2022-07-28 | 재개 | B. Riley Securities | Buy |
| 2022-04-11 | 개시 | H.C. Wainwright | Buy |
| 2022-02-15 | 개시 | Goldman | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-25 | 개시 | Citigroup | Buy |
| 2021-02-18 | 개시 | B. Riley Securities | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-05-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-04 | 개시 | Robert W. Baird | Outperform |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 개시 | FBR & Co. | Outperform |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-10-07 | 개시 | Guggenheim | Buy |
| 2016-03-28 | 개시 | Citigroup | Buy |
| 2016-03-28 | 개시 | JMP Securities | Mkt Outperform |
| 2016-03-28 | 개시 | Morgan Stanley | Overweight |
모두보기
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Syndax Pharmaceuticals to Report Second Quarter 2026 Financial Results and Host Conference Call on August 4 - Quiver Quantitative
Syndax will give a cancer-therapy business update Aug. 4 - Stock Titan
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026 - GlobeNewswire
Syndax Pharmaceuticals, Inc. $SNDX is Eversept Partners LP's 6th Largest Position - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Cash Flow - TradingKey
Syndax Pharmaceuticals Inc (SNDX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Syndax Pharmaceuticals (SNDX) Projected to Announce Quarterly Earnings on Monday - MarketBeat
Orbimed Advisors LLC Invests $22.48 Million in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
SNDX|Syndax Pharmaceuticals Inc|Price:20.810|Chg%:-0.400 - TradingKey
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Granahan Investment Management LLC Cuts Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Price to sales forward of Syndax Pharmaceuticals Inc – SWB:1T3 - TradingView
Syndax Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:SNDX - TradingView
Syndax Pharmaceuticals, Inc. (SNDX) Investor Outlook: A Promising 83.88% Upside Potential - DirectorsTalk Interviews
Syndax Pharmaceuticals Inc. (SNDX) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Technical Reactions to SNDX Trends in Macro Strategies - Stock Traders Daily
Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $37 - Moomoo
Syndax Pharmaceuticals (SNDX) Receives a New Rating from a Top Analyst - The Globe and Mail
Syndax Pharmaceuticals (SNDX) FDA Announcement Summary - Quartr
Syndax Pharmaceuticals (SNDX) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Syndax Pharmaceuticals Holds Steady Near Support at $22.8 After Modest GainExhaustion Gap - dars.gov.et
Syndax Pharmaceuticals Inc. (SNDX) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Syndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should Know - Yahoo! Finance Canada
Syndax Pharmaceuticals (SNDX) Could Be 40% Undervalued As Pipeline Updates Sharpen Growth Story - Sahm
SNDX Stock Price, Quote & Chart - ChartMill
Goldman Sachs Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (HCA) and Syndax Pharmaceuticals (SNDX) - The Globe and Mail
TD Cowen Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating - Moomoo
SNDX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Syndax Pharmaceuticals unveils new pipeline candidates - BioWorld News
Syndax Pharmaceuticals (NASDAQ:SNDX) Earns "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright reiterates Syndax Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $57 - Moomoo
Syndax Showcases Late-Stage Pipeline, Expands R&D Strategy - TipRanks
SNDX6417984 Bond Coupon Profile — Rate & Payments - TradingView
Syndax Pharmaceuticals Inc to Host R&D Day Transcript - GuruFocus
SNDX6417984 Bond Profile — Key Metrics - TradingView
A Fresh Look At Syndax Pharmaceuticals (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push - MarketBeat
Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead TherapiesSlideshow (NASDAQ:SNDX) 2026-07-14 - Seeking Alpha
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet - Yahoo! Finance Canada
SNDX: New pipeline assets and late-stage programs drive clinical and commercial growth through 2027 - TradingView
Syndax (NASDAQ: SNDX) details pipeline expansion and 2026-27 clinical catalysts - Stock Titan
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event - The Manila Times
Form 4 Syndax Pharmaceuticals For: 9 July By Investing.com - Investing.com Nigeria
Syndax CEO Michael Metzger sells $784,776 in company stock By Investing.com - Investing.com Nigeria
Syndax CEO Michael Metzger sells $784,776 in company stock - Investing.com
Syndax Pharmaceuticals Insider Sold Shares Worth $784,776, According to a Recent SEC Filing - Moomoo
Syndax (SNDX) CEO Metzger exercises options and sells 32,375 shares under 10b5-1 plan - Stock Titan
Syndax Pharmaceuticals Inc (SNDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Syndax Pharmaceuticals Inc 주식 (SNDX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Metzger Michael A | Chief Executive Officer |
Jul 08 '26 |
Sale |
24.24 |
32,375 |
784,776 |
484,843 |
2.44%
0.02%
자본화:
|
볼륨(24시간):